BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
01/28/2021
Initial Lawsuit
01/28/2021
Lawsuit Progression
06/10/2021
Investigation an SEC investigation regarding overvaluation of Exxon’s mort important oil and gas properties in the Permian Basin.
01/15/2021
The Wall Street Journal reports that the SEC launched an investigation of Exxon Mobil after an employee filed a whistleblower complaint alleging overvaluation of its key assets in the Permian Basin. According to the class action complaint, the stock price fell $2.42 per share, or 4.81% on January 15, 2021 because of this news.
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$46.41 | $48.753646016644 | $-2.34 | -4.81% |
Plaintiff brings this securities class action on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Exxon securities between November 6, 2019 and January 14, 2021, both dates inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) Exxon forced its employees to use unrealistic assumptions regarding the timelines for well drilling in the Permian Basin;
(ii) the foregoing assumptions served to artificially inflate the value of the Company’s well
operations in the Permian Basin;
(iii) the foregoing conduct, when revealed, subjected Exxon to a heightened risk of regulatory investigation and oversight; and
(iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
06/10/2021
The court issued an order appointing the lead plaintiff and lead counsel.
09/10/2021
Plaintiffs bring this federal securities class action on behalf of themselves and a class consisting of all persons and entities who purchased, or otherwise acquired, the common stock of Exxon from March 7, 2018 to January 15, 2021, inclusive.
Operative complaint
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.